Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lundbeck/Myriad Marriage: Short But Not Sweet

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III data on Alzheimer’s disease candidate Flurizan comes up short.

Related Content

Lilly's Semagacestat Is Latest Alzheimer's Drug To Fail; Is Class At Risk?
Lilly To Cease Development of Phase III Alzheimer's Drug
Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Whatever Works – Or Might: Pfizer/Wyeth Likely To Keep Both Alzheimer’s Bets
Debt Clock, Cash Situation Push Elan To Explore Options – Sale, Alliance, Merger?
Alzheimer’s Player Satori Wades Into Fray With Mystery Technology – And $22 Million
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
Pfizer Finds Backup For Aricept In Medivation’s Dimebon
Myriad Weighs Strategic Alternatives
Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts